Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
BioVersys (BIOV.XSWX) generated about CHF 800,000.00 in revenue and -CHF 22 million in net income (a -2,728.8% net margin) over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
BioVersys generated about CHF 800,000.00 in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
BioVersys reported about -CHF 22 million in net loss over the trailing twelve months, a net margin of roughly -2,728.8%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
BioVersys runs a gross margin of about -386.6%, an operating margin of about -2,495.4%, a net margin of about -2,728.8%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.